Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272649 · ClinicalTrials.gov registry record · Phase 1
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
A Phase 1 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 10
- Study locations
NCT00272649: Completed Phase 1 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.
NCT00272649 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Argos Therapeutics. The registered enrollment target is 22 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00272649, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with metastatic kidney cancer
Conditions Studied
Interventions
- BIOLOGICAL AGS-003
Study Locations (10)
California
- UCLA Kidney Cancer Program - Los Angeles
Colorado
- Univ. of Colorado Health Science Center - Division of Medical Oncology - Aurora
Georgia
- Emory University - Atlanta
Indiana
- The Indiana University Cancer Center/IUPUI - Indianapolis
Nevada
- Nevada Cancer Institute - Las Vegas
New York
- Roswell Park Cancer Institute - Buffalo
North Carolina
- Carolinas Medical Center/Blumenthal Cancer Center - Charlotte
Oregon
- Earle A. Chiles Research Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT00272649 record still lists
NCT00272649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AGS-003 is the first listed.
NCT00272649 lists 10 locations in 10 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT00272649 about?
NCT00272649 is a clinical study titled "Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer". The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with metastatic kidney cancer
What is the current status of trial NCT00272649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2012-02.
What conditions does trial NCT00272649 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT00272649?
The interventions under investigation include: AGS-003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00272649?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00272649 being conducted?
This trial has 10 study locations across California, Colorado, Georgia, Indiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00272649's enrollment target sits among peer trials
22 105th of 121 higher than 15 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia